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Humoral  immune  responses  are  known  to  be  regulated,  both  positively  and 
negatively, by antigen- and idiotype-specific T  lymphocytes. Despite the large body 
of evidence supporting this notion (1-3), the mechanisms by which T  cells influence 
B  lymphocyte differentiation and  function are largely unknown.  One of the major 
reasons for this is the vast heterogeneity of the immune system, so that only very few 
lymphoid cells in an individual are committed to recognizing and responding to any 
defined antigenic determinant. As one approach to investigating the regulation of B 
lymphocytes and antibody secreting cells, we, as well as others, have focused on the 
development of antigen-specific myelomas as model systems for lymphoid cells because 
such homogeneous tumor lines are amenable to detailed biochemical and morphologic 
analyses  (4,  5).  It  is  now  established  that  the  function  of myeloma  cells  can  be 
regulated by tolerogenic antigens and immune complexes (6, 7), carrier-specific helper 
and  suppressor  T  cells  (8),  idiotype-reactive T  lymphocytes  (9-11),  and  hapten- 
specific cytolytic T  cells (12). 
Recently, we have described two types ofT cells that specifically suppress myeloma 
function in vitro. The first (10)  is an idiotype-reactive suppressor T  cell (Ts),  a which 
is induced by immunizing BALB/c mice with syngeneic cells to which the BALB/c 
myeioma protein,  M315  (IgA,~k~), is  covalently coupled.  Such  Ts  inhibit  antibody 
secretion by MOPC 315 cells in vitro in the absence of any antigen without affecting 
cell growth or viability; moreover, these T  lymphocytes, similar to Ts in other systems, 
bear surface determinants encoded by the  I-J subregion of the  H-2 complex, their 
precursors are sensitive to cyclophosphamide, and they can be bound to plastic dishes 
coated with the M315 myeloma protein (10). The anti-idiotypic specificity of these Ts 
was established by their inability to bind to plastic dishes coated with M460 myeloma 
protein, which,  like M315,  binds  2,4-dinitrophenol  (DNP)  and  2,4,6-trinitrophenol 
(TNP)  but  does  not  share  idiotypic determinants  with  M315.  The second  type of 
* Supported by National Institutes of Health grants AI-14478, AI-16349, CA-14723, AI-16396, and AI- 
13357. 
i Abbreviations used in this paper: ABA, p-azobenzenearsonate;  CTL, cytolytic  T lymphocyte(s);  DNP, 2,4- 
dinitrophenol; ECDI, I-ethyl 3-(3-diaminopropyl) carbodiimide; FCS, fetal calf serum; KLH, keyhole 
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regulatory T  cell  (12)  is  a  BALB/c cytolytic T  lymphocyte (CTL)  specific for the 
hapten, TNP, which inhibits antibody secretion by TNP-binding MOPC 315 cells in 
the presence of soluble TNP-coupled keyhole limpet hemocyanin (KLH). The inter- 
action of  CTL and TNP-binding myelomatargets is read out as functional suppression 
of the myeloma cells and is followed by a  subsequent reduction in viable myeloma 
cell recovery, which  suggests  that  the inhibition of antibody secretion is a  prelytic 
effect of the T  cells. These effector T  lymphocytes, like classical hapten-reactive CTL 
described by other investigators (13), are Thy-1 and  Ly-2 positive, hapten specific, 
radioresistant,  and  H-2 restricted;  their precursors are  insensitive to cyclophospha- 
mide; and  they do not bind to plastic dishes coated with TNP-proteins. Moreover, 
only myeloma cells that bind the TNP-protein to anti-TNP membrane receptors are 
suppressible by hapten-specific CTL (12). We have proposed that this system provides 
a model for further investigation of the interactions between H-2-restricted, antigen- 
specific T  lymphocytes and antigen-specific targets such as B cells. In addition, these 
experiments support the possibility that  hapten-reactive CTL can function as regu- 
lators of physiologic anti-hapten antibody responses (12). 
To  further analyze  the  mechanisms  by  which  idiotype-specific Ts  and  hapten- 
reactive CTL  affect  myeloma cell  function,  we  have  examined  their  effects on  a 
hybrid  cell  line  generated  by  fusing  MOPC  315  cells  with  the  IgG2b,•-secreting 
myeloma MPC  11. Our previous experiments have established the specificity of the 
T  lymphocytes in terms of recognition, i.e., idiotype-reactive Ts recognize idiotypic 
determinants on myeloma proteins in the absence of exogenous antigen (10), whereas 
syngeneic hapten-reactive CTL recognize receptor-bound hapten apparently in asso- 
ciation with surface determinants encoded in the H-2 complex (12). The use of the 
hybrid  cell  line  now  permits  us  to  analyze whether  the  mechanisms  of myeloma 
suppression  by these  distinctly different T  lymphocytes are  the same  or not.  The 
particular  issue  we  have  addressed  is  whether  the  interaction  of a  regulatory  T 
lymphocyte with such a  hybrid myeloma cell will affect production of one or both 
immunoglobulins  (Ig)  secreted by the  hybrid.  The major conclusion is  that  TNP- 
specific CTL, in the presence of TNP-KLH, suppress the secretion of both Ig by the 
hybrid cells, whereas idiotype-specific Ts inhibit secretion of only the Ig bearing the 
appropriate idiotype. The implications of these findings for the mechanism of action 
of regulatory T  lymphocytes are discussed. 
Materials and Methods 
Cell Lines, Myeloma Proteins, and Antigens.  BALB/c myelomas MOPC  315  (which  secretes 
IgA,h2 antibody specific for DNP and TNP) and MPC  11  (IgG2b,K  of unknown specificity) 
were tissue culture-adapted lines that have been described in detail in previous  publications 
(14, 15). By plaque assays, only 40-70% of the myeloma cells secrete Ig at any time (14, 15); 
whether this is related to the stage of the cell cycle or to the presence of distinct subpopulations 
within each myeloma line or to other factors is a question that is currently being investigated. 
Hybrids between these  parental  lines were derived by polyethylene glycol fusion  and were 
selected and cloned on the basis of their ability to secrete one or both Ig isotypes  (15). The 
MOPC 315-MPC  11 hybrid used in these studies has been referred to as the S001 line in earlier 
papers (15). This line secretes both IgG2b,•  and IgA,h2 molecules, with virtually all (>90%) x- 
chains being IgG2b associated,  and the majority of the ~2-chains being IgA associated  (15). 
After subcloning,  the rate of spontaneous loss of IgG2b,K in the hybrid line is < 1 in 105 cells per 
generation, and of IgA is < 1 in 103 cells per generation (16). Analyses of cell-surface Ig in such 
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isotypes in amounts similar to those seen in the parental lines (16) (G. Siebert and M. L. Gefier. 
Unpublished data.).  All myeloma lines  were maintained  in suspension culture in Dulbecco's 
modified  Eagle's medium with  penicillin,  streptomycin, nonessential  amino acids,  and  20% 
heat-inactivated fetal calf serum (FCS)  (Grand Island Biological Co., Grand Island, N. Y.) at 
37°C in a humidified atmosphere of  5% CO2. P815 (DBA/2 mastocytoma) cells were maintained 
in ascites form. 
M315  protein  was  purified  from  ascites  of tumor-bearing  mice  by  ammonium  sulfate 
precipitation  (45% saturation)  and affinity chromatography on DNP bovine serum albumin- 
coupled Sepharose 4B (10).  MPC  11  protein was purified from tumor aseites by binding to 
staphylococcal protein A-Sepharose and elution with 0.1  M  acetate buffer (pH 4).  For some 
experiments this protein was further purified by ion-exchange chromatography on Sephadex 
QAE-A25 (17).  Hapten  (TNP) conjugates of KLH were prepared as described by Ballas and 
Henney (18). The conjugates used in these experiments were TNP2sKLH and TNP30KLH (28 
and 30 mol of TNP/100,000 mol wt of KLH). 
Generation ofldiotype- and Hapten-reactive Lymphocytes.  Ts reactive with myeloma idiotypes were 
generated  as  described  previously  (10).  Briefly,  4  ×  l0  s  BALB/c spleen  lymphocytes were 
coupled with 2 mg of M315 or MPC 11 protein, with 1-ethyl 3-(3-diaminopropyl) carbodiimide 
(ECDI) as the coupling reagent.  Under these conditions, the coupling efficiency was 5-10%, 
and the cells were 60-80% viable by trypan blue dye exclusion. BALB/c mice were immunized 
intravenously with 5 ×  107 viable myeloma protein-coupled or control (ECDI-treated) cells. 
Spleens and thymuses were removed 7 d  later,  freed of erythrocytes by treatment  with Tris- 
buffered 0.83% NH4CI, and spleen cells were passed through nylon-wool columns to collect the 
nonadherent fraction (<7-10% surface Ig positive by immunofluorescence). Binding ofidiotype- 
reactive Ts to myeloma protein-coated plastic dishes was done as previously described (10). 
CTL specific for TNP were generated by in vitro stimulation of BALB/c spleen cells with 
1,500-rad x-irradiated, TNP-modified syngeneic splenocytes (19). Cytolytic activity was meas- 
ured by 4-h 51Cr-release assays (19). 
Myeloma Cell Cultures and Assays  for Antibody Secretion.  These techniques have been described 
in detail previously (10,  12). Viable myeloma cells were isolated by centrifugation over Ficoll- 
Isopaque, and  10  s cells  were cultured  in triplicate with  idiotype-reactive Ts or TNP-specific 
CTL in  fiat- or round-bottom microcuhure plates  (Linbro Chemical Co., Hamden,  Conn.), 
respectively. Cultures were done in total  vol of 0.2 ml  RPMI-1640 (Grand Island Biological 
Co.) with penicillin, streptomycin, 10% FCS, 10 mM Hepes, and 5 ×  10  -5 M 2-mercaptoethanol 
at 37°C in a humidified atmosphere of 5% CO2. At the end of 1-5 d of culture, the cells were 
harvested, washed twice, and aliquots were assayed by reverse hemolytic plaque assays with 
protein A-coated sheep erythrocytes as indicator cells (10, 20). Preliminary experiments estab- 
lished  the specificity of this assay: with  rabbit  anti-MPC  11  serum,  only MPC  11  but  not 
MOPC 315  plaque-forming cells  (PFC) were detected, and the reverse was true with rabbit 
anti-M315  developing serum.  After cocuhure with  idiotype-reactive Ts,  an  aliquot  of each 
culture was also assayed for viable myeloma cell  recover.y-(viability being judged by trypan 
blue dye exclusion). Results are expressed as PFC ×  10-a/culture, or PFC/103 recovered viable 
myeloma cells. 
Results 
Effects of ldiotype-reactive  Ts on Myeloma  Cells.  Thymic and nylon-wool nonadherent 
splenic T  cells from BALB/c mice immunized intravenously with M315- or MPC  11- 
coupled syngeneic splenocytes were cultured  with  the parent  myeloma lines  or the 
hybrid cells for 4  d, after which Ig secretion by the myeloma cells was measured.  As 
shown  in  Table  I, T  lymphocytes  from  mice  immunized  with  M315-coupled  cells 
suppress  antibody  secretion  by  MOPC  315  but  not  MPC  11  cells,  and  vice versa. 
Moreover, when the hybrid cells are analyzed, M315-specific Ts inhibit IgA secretion 
only, whereas MPC  11-specific Ts suppress IgG secretion only. Pooled data from four 
experiments  done  with  the  hybrid  line  are  shown  in  Table  II,  supporting  this 
conclusion.  Several  points  are  noteworthy.  First,  comparable  suppression  is  seen 972  SUPPRESSION  OF HYBRID  MYELOMA CELLS 
TABLE  I 
Effect  of Idiotype-reactive  Ts on MOPC 315, MPC  11, and Hybrid Myeloma  Cell Lines 
IRA PFC  IgG PFC 
Mycloma cells 
Ill  '+ thymocytes  PFC/II/' vi-  PFC/I(I:~ 
from  mice in-  PFC ×  PFC ×  viable 
able mye-  I0  :t/ctdturt-  myelon~a  iccted intrave-  10  :~/cultutc  t,.  toma cells  P  P 
nously  with  (mean ±  (mean ±  cells 
(mean ± 
,SE)  SE)  (mean ± 
.SE)  SE~ 
MOP(/315 
MOPC  :315 
MOPC 
MPC I I 
MPC I I 
MPCII 
MOPC  315-MPC 
hybrid 
MOPC  315-MPC 
hybrid 
MOPC  315+MP(  1 
hybrid 
N<me  40.3 ±  4, I  656 :t: 41  0 
M315 cells  17.9 +  1.5  <0.01  363 ±  22  <0,(~)5 
MPC I I cells  39.2 ±  8.2  NS:~  51i7 ±  142  NS 
None  I)  71.9 +  46  691  ±  45 
M315 cells  7231 ±  4.8  NS  692 ±  47 
MPC  I I cells  47.5 ±  4.7  <0.115  371  ±  45 
None  43.6 ±  3.2  498 +  :37  47.9 ±  2.2  547 ±  25 
M315 cells  20.9 ±  4.0  <0.05  248 ±  47  <0.O5  51.3 ±  6.5  NS  607 ±  77 
MPC I I ccHs  41.0 ±  4.6  NS  445 ±  51)  NS  :t28 ±  3.3  <11.112  357 ±  :36 
<0,(11 
NS 
<O,IH 
I0  + myeloma cells were cultured  in triplicate with  l0  n thynmcytes fi-om mice injected intravenously  7 d  previous b' with M:315- oT MPC  I I-coupled 
splenocytcs.  After 4  d  of culture at  :37°C,  the cells  were washed,  and  allquots were  assayed  for  IgA and  Iff(;  PFC as well am  viable myeloma cell 
Fecovel'} + 
* ('ulculated  by  Studenl+s  I  tests,  with  gl'OtlpS containing  myeloma  ceils alone  am  conllolS,  (h'oups  showing  significant  hfifibiti.n  (/' <  0,(15) art' 
underlined+ 
:~ NS, not significant. 
TABLE II 
Effect of Idiotype-reactive  Ts on MOPC 315-MPC  l 1 Hybrids 
Sttp})res,  sor cells  IgA PFC  lgG PFC 
PFC/I I)  :~  PFC/l I)  :~ 
PFC x  PFC × 
vlablc  viabh" 
lntta'¢ellotls  IO  :l/ctdture  Ill  3/cuhtll'e 
Cells  P*  myelunla  I'  I'  nlyelonla  1' 
irtlmUili~a~io;I  [llz(~all ±  (nz(ratl ± 
cells  (nwan  cc[[s (nit'an 
SE  I  Sl:l 
+  SE)  +  SE) 
None  43,4 ±  3.1  459 ±  27  44.5 ±  2.1  486 ::1:26 
ECDI cells  I-2 ×  10  ~ thymus  38.1  ±  3.9  NS:~  362 ±  53  NS  43.6 ±  2.9  NS  403 +  :34  NS 
EC1)I cells  I-2 ×  10  ~ spleen  4:3.9 ±  6.9  NS  490 ±  99  NS  48.2 4- 3.2  NS  496:1:20  NS 
M315 cells  I-2 X  106 thymus  25.4 ±  2.0  <0.001  316 ±  26  <0.001  43.2 +  3.2  NS  5:35 ±  38  NS 
M315 cells  1-2 X  10  ~ spleen  22.1  -t- 3.0  <0.001  241  ±  41  <0001  44.4 ±  :3.5  NS  518 ±  :34  NS 
MPC 11  cells  I-2  X  106 thymus  43.8 ±  3.8  NS  556 ±  52  NS  31.3 ±  3.0  <0+005  391  ±  39  NS 
MPC I I cells  I-2 ×  10  ~ spleen  43.7 -t- 5.2  NS  481  ±  50  NS  32.6 +  1.7  <0.001  360 ±  21  <0.IN)5 
M315 cells  3 ×  l0  a thymus  14.7 ±  1.9  <0.001  186 -I- 25  <0,001  36.3 ±  2.3  NS  459 ±  :30  NS 
MPC I I cells  3 ×  l0  ~ thymus  28.8 ±  1.4  >0.03  :335 ±  17  >003  28.1  +  4.2  <0.005  327 ±  49  <0.02 
I0" MOP(  2 315-MPC 1 I hybrid cells  were cultured in  triplicate with BAI,B/c thymic ot  nylon-wool  nonadhercnt  splenic T  lymphocytcs fixm[ mice 
that had been immunized intravenously 7 d  previously  with M315- ol  MP(  3 I I-coupled or control  (ECl)l-treated) syngeneic splenocytcs. Aftcl 4 d of 
culture at 37°C, the cells were washed and assayed for lgA and Ig(; PFC and viable mycloma cell  iccovery.  I)ala are pooled  fi'onl  foul experlmcnts 
" (;alculated by Sttldent's t tests with cuhures of h~btid myeloma cells  alone a~ controls+ Groups showing significant inhibition ale underlined. With 3 
×  10  f+ thymo,zytes,  MPC  1 l-reactive Ts do Sttl)l+te~s lgA PFC (1' <  IL05 >  003) but to a  much lesser extent than  M',llS-teactixc Ts. 
:~ NS. not significant 
whether  the  results  are  expressed  as  PFC/culture  or  PFC/10 a  viable  recovered 
myeloma cells,  which  indicates  that  the  Ts  are  not  cytostatic  or cytolytic.  This  is 
further supported by our findings that such suppressor cells do not significantly affect 
viable myeloma cell recovery after up to 5-d of coculture, and the suppressors are not 
lytic for myeloma targets by mCr-release assays (data not shown). Second, intravenous 
immunization with  splenocytes  treated  with  ECDI  in  the  absence  of any myeloma 
protein does not generate suppressor cells (Table II). Third, the degree of suppression ABBAS, BURAKOFF,  GEFTER,  AND GREENE  973 
generally  observed  is  40-60%  for  MOPC  315  cells,  which  is  similar  to  previously 
published  results  (10),  and  25-45%  for MPC  l I.  Increasing the  number of Ts does 
increase the degree of suppression,  but with -->3 X  106 idiotype-specific Ts or control 
cells, nonspecific effects are seen (Table II), and under no conditions have we observed 
100%  inhibition  of Ig secretion.  Whether  these  limits  on the degree of inhibition  of 
PFC are because only a proportion of the myeloma cells express high-density receptor 
Ig molecules, as we have proposed earlier (10), or because of other factors, is a question 
that is currently being explored. Finally, kinetic analyses have shown that significant 
suppression  of both  parent  and  hybrid  cell  lines requires  3-4 d  of coculture with T 
lymphocytes, which is similar  to published  observations with the MOPC  315 parent 
line  (10).  Moreover,  we have  never  observed  an  enhancement  of PFC  induced  by 
idiotype-immune T  cells in either parent  or hybrid myeloma line  (10). 
To  confirm  the  specificity  of  these  Ts,  thymic  or  splenic  T  cells  from  mice 
immunized  intravenously  with  M315-coupled  or MPC  11-coupled splenocytes were 
plated on plastic dishes coated with either myeloma protein. The nonadherent fraction 
was then cocultured with the hybrid myeloma cell line for 4 d, and antibody secretion 
was measured.  As shown  in Table III, M315-reactive Ts inhibit  only IgA secretion, 
and  this  effect  is lost  by depleting  the Ts on  M315-coated  but  not  MPC  11-coated 
dishes,  and  the  reverse  is  true  of MPC  11-reactive  Ts.  These  experiments  establish 
that  the  Zs  recognize  unique  determinants  of the  appropriate  myeloma  proteins. 
Because  isologous  immunization  with  myeioma  proteins  induces  anti-idiotypic  im- 
munity, we refer to the Ts as "idiotype specific," although we have not demonstrated 
whether  they  recognize  unique  determinants  in  the  combining  sites,  framework 
regions, or other regions of the myeloma Ig. 
Effects of Hapten-specific  CTL on myeloma  Cells.  BALB/c TNP-reactive CTL gener- 
ated by in vitro stimulation  and x-irradiated  were cultured  with  MOPC  315,  MPC 
11,  and  hybrid  cells  with  or without  TNP-KLH.  As shown  in Table  IV, coculture 
only in  the  presence  of soluble  antigen  leads  to inhibition  of antibody secretion  by 
MOPC  315 cells but not by MPC  11 cells, which lack membrane receptors for TNP. 
TABLE III 
Depletion of Idiotype-reactive Ts on Dishes Coated with myelorna Proteins 
2 X 10  ~ suppressor cells  Percent inhibition 
(mean) 
Intravenous prim-  Depleted on  lgA PFC  IgG PFC 
ing 
M315 cells  None  37.4  11.8 
M315 cells  M315-coated  dish  2.3  ND* 
M315 cells  MPC l 1-coated dish  33.9  ND 
MPC 11 cells  None  1.7  44.5 
MPC 11 cells  M315-coated  dish  ND  41.2 
MPC 11 cells  MPC I l-coated dish  ND  8.7 
10  '~ MOPC 315-MPC 11 hybrid cells were cultured with 2 ×  10  n splenic or 
thymic T cells generated by intravenous immunization and treated as shown. 
After 4 d of culture, |gA and IgG PFC were assayed. Results are pooled from 
four experiments and normalized and expressed as percent inhibition of PFC 
per culture compared with control cultures of myeloma cells alone. Groups 
showing significant inhibition (P< 0.05) in each experiment are underlined. 
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TABLE  IV 
Effect of TNP-reactive CTL and TNP-KLH on MOPC 315, MPC 11, and Hybrid Cell Lines 
IgA PFC x  IgG PFC x 
TNP28-  3 ×  105 effector  10-a/culture  p,  10_3/cultur  e 
Myeloma cells  KLH  cells  (mean ± 
SE)  (mean ±  SE) 
MOPC 315  None  None  45.4 :t: 2.6  -  0 
MOPC 315  50 #g/ml  None  35. I ±  2.4  - 
MOPC 315  50 #g/ml  Anti-TNP CTL  18.3 ±  2.6  <0.001 
MOPC 315  None  Anti-TNP CTL  39.4:1:3.6  NS¢ 
MPC  11  None  None  0  62.1 ±  4.4 
MPC 11  50 #g/ml  None  54.0 ±  2.9 
MPC I l  50 #g/ml  Anti-TNP CTL  50.6 +  3.4 
MPC  11  None  Anti-TNP CTL  60.1 ±  3.5 
MOPC  315-MPC  11  None  None  40.5:1:11.6  -  37.6 ±  1.6 
hybrid 
MOPC  315-MPC  11  50 #g/ml  None  44.7 4- 2.7  -  38.0 ±  2.3 
hybrid 
MOPC  315-MPC  11  50 #g/ml  Anti-TNP CTL  26.8 +  0.9  <0.001  22.0 ±  0.3 
hybrid 
MOPC  315-MPC  11  None  Anti-TNP CTL  34.5 ±  3.1  NS  32.1 ±  2.8 
hybrid 
51Cr-labeled  target 
NS 
NS 
<0.001 
NS 
Assays for eytolysis of TNP-modified and 
unmodified 51Cr-labeled  targets by 
TNP-reactive CTL revealed the fol- 
lowing in one representative experi- 
ment: specific lysis by anti-TNP CTL 
at effector:target ratio of: 
20:1  80:l 
TNP-modified P815 
Unmodified P815 
TNP-modified MOPC 315 
Unmodified MOPC 315 
TNP-modified MPC  I l 
Unmodified MPC  11 
TNP-modified MOPC 315-MPC 11 hybrid 
Unmodified MOPC 315-MPC  11 hybrid 
58.0  82.9 
6.7  21.0 
91.2  98.3 
19.6  27.0 
63.6  69.0 
0  8.6 
58.6  95.1 
0  10.7 
105 myeloma cells were cultured in triplicate with and without TNP28KLtt  and  3 ×  105  1,500-R  x- 
irradiated TNP-reactive CTL generated by in vitro stimulation. At the end of 24 h  at 37°C, the cells 
were washed three times, and aliquots were assayed for IgA and IgG PFC. 
* Calculated by Student's t tests, with groups containing myeloma cells and the equivalent concentration 
of antigen but lacking CTL as controls. Groups showing significant inhibition are underlined. Data are 
pooled from two representative experiments. 
:~ NS, not significant. 
Hybrid  cells  show  inhibition  of  both  IgA  and  IgG  secretion,  which  is  strikingly 
different  from  the  effects  of idiotype-specific  Ts.  In  the  absence  of antigen,  TNP- 
specific CTL  have  no significant effect.  Similar results have been  obtained  with  10- 
100/.tg/ml  of TNP-KLH.  Moreover,  all three tumor  cell lines can be lysed  by TNP- 
specific CTL  if the targets are directly haptenated  (Table  IV), but  no lysis is seen in 
4-h 'SICr-release assays with unmodified  targets alone (Table IV) or unmodified  targets 
incubated  with soluble antigen  (data not shown). Finally, when  MOPC  315 or hybrid 
cells are cocultured  with TNP-KLH  and  1,500-R  x-irradiated  anti-TNP  CTL  for 24 ABBAS, BURAKOFF, GEFTER, AND GREENE  975 
h, washed, and aliquots recultured in fresh medium, after 2-3 d the viable myeloma 
cell recovery is reduced by 25-50% compared with control cultures of myeloma cells 
alone. This suggests that the functional inactivation of myeloma targets is followed 
by target-cell death. 
Discussion 
These experiments show that the function of an antigen-binding hybrid myeloma 
cell line can be altered in strikingly different ways by different types of regulatory T 
lymphocytes. Thus, hapten-reactive CTL, in the presence of soluble hapten proteins, 
inhibit the secretion of both Ig by the hybrid myeloma line, whereas idiotype-reactive 
Ts suppress secretion of only the Ig bearing the relevant idiotype. 
The  finding of highly specific,  differential suppression  of Ig  secretion  by  anti- 
idiotypic  Ts  has  important  implications  for  the  mechanisms  of action  of such 
regulatory T  cells.  It  should  be  pointed out  that  the  rate  of spontaneous  loss  of 
expression of one Ig by the hybrid line is so low (16) that such differential suppression 
cannot  be accounted for by any form of spontaneous loss of production of one Ig 
during culture. These experiments establish the specificity of idiotype-reactive Ts at 
two levels.  First, suppressor cells induced by intravenous immunization with M315- 
or MPC 11-coupled syngeneic splenocytes are clearly specific in terms of recognition, 
because they inhibit only the appropriate parent myeloma line (Table I) and bind to 
the  appropriate  myeloma protein  (Table  III).  Second,  each  idiotype-reactive Ts 
population inhibits the secretion of only the Ig bearing that idiotype by the hybrid 
line (Tables I and II). This selective effect of the Ts on the function of hybrid myeloma 
cells can be accounted for by one of two mechanisms. It is conceivable that suppression 
is a  surface phenomenon, perhaps related to the binding of an anti-idiotypic factor 
released  from  Ts  to  the  myeioma cells,  which  results  in  a  secretory blockade  or 
absorption of the secreted idiotype. Such a mechanism is supported by the studies of 
Rohrer et al.  (9),  who have found that  MOPC  315  cells enclosed within diffusion 
chambers and implanted in the abdomens of M315 idiotype-immune BALB/c mice 
show an idiotype-specific secretory blockade that is reversed by treating the myeloma 
cells  with  pronase.  In  our  in  vitro  system, pronase  treatment  fails  to  reverse  the 
inhibition of myeloma cells that have been cocultured with idiotype-reactive Ts (data 
not  shown).  The  alternative  possibility is  that  the  inhibitory signal  delivered  by 
idiotype-specific Ts affects only that portion of the Ig-producing apparatus of the cell 
that is related or linked to the surface idiotype. The intracellular sequence of events 
that could lead to such an effect is unknown. Attempts are currently under way to 
develop experimental conditions for inducing maximal idiotype-specific inhibition of 
myeloma cells in vitro so that the molecular basis of this inhibition can be analyzed. 
Nevertheless,  irrespective of the precise  mechanism, these results indicate that  the 
effector function of idiotype-reactive Ts is highly specific in that it can affect one but 
not another highly specialized function of an appropriate target. Moreover, it is also 
clear that in this system, functional inactivation is not accompanied by cell death. We 
do not know if classical, nonlytic, antigen-specific Ts will have an effect similar to 
idiotype-specific Ts. Experiments are currently in progress to determine if hapten- or 
carrier-reactive Ts will alter myeloma function in  vitro in the presence of hapten- 
carrier conjugates. 
The  observation  that  syngeneic anti-TNP  CTL,  in  the  presence  of TNP-KLH, 976  SUPPRESSION  OF  HYBRID  MYELOMA  CELLS 
inhibit the secretion of both IgA and IgG by the MOPC  315-MPC  11  hybrid line 
(Table IV)  is consistent with earlier results that suggest that functional suppression 
represents  a  prelytic effect of these T  iymphocytes (12).  This view is supported by 
experiments done by ourselves and others (21-23) showing that functional inactivation 
of myeloma and mastocytoma targets is a highly sensitive assay for classical, alloreac- 
tive CTL, and appears to reflect a  prelytic abnormality induced by the CTL. The 
failure of anti-TNP CTL to interact with MPC  11  cells has been  reported earlier, 
and,  taken  together with experiments  utilizing double  conjugates of TNP  and p- 
azobenzenearsonate  (ABA)  with KLH and ABA-reactive CTL, indicates that only 
antigen  bound  to  specific  membrane  Ig  receptors  renders  the  myeloma  targets 
suppressible by hapten-reactive CTL (12).  Thus, once TNP-KLH is bound to anti- 
TNP receptors on the MOPC 315-MPC  11 hybrid cells, syngeneic TNP-reactive CTL 
interact with these cells and inhibit production of both Ig isotypes. The subsequent 
reduction  of viable  myeloma cell  recovery  after  more  prolonged  culture  in  fresh 
medium would indicate that such suppressed myeloma targets are probably commit- 
ted to lyse. 
Finally, the  relevance  of these  experiments  to  T  cell  regulation  of physiologic 
humoral immune responses must be considered. We, as well as others, have presented 
experimental evidence supporting the concept  that  myeloma cells are  valid model 
systems for analyzing lymphocyte function (4, 5), although it is unclear to what extent 
a  fusion-derived hybrid myeloma line differs from parental  lines. Nevertheless, the 
studies reported in this paper suggest that regulation of B cell function might occur 
by one of two mechanisms. Idiotype-reactive and, possibly, antigen-reactive Ts that 
are nonlytic can inhibit immunocompetent cells expressing the appropriate receptors 
on their surface without irreversibly injuring these cells,  Such a  mechanism would 
represent a  form of clonal inhibition. In contrast, antigen-reactive CTL, which may 
also play a role in regulating humoral immunity (12), would accomplish this by clonal 
deletion. Whether such mechanisms can actually be distinguished in different kinds 
of physiologic immune responses and their regulation remains to be answered. 
Summary 
To investigate the mechanisms by which T lymphocytes regulate myeloma function 
in vitro, the effects of regulatory T  cells on antibody secretion by a hybrid myeloma 
cell line were examined. Suppressor T  cells (Ts) specific for idiotypic determinants on 
M315  (IgA,~ anti-2,4-dinitrophenol and anti-2,4,6-trinitrophenol [TNP])  and MPC 
11  (IgGzb,~¢) myeloma proteins inhibit antibody secretion by the appropriate parental 
myeloma cells. When cocuhured with a hybrid cell line derived by fusion of MOPC 
315  and MPC  11  myelomas, the idiotype-reactive Ts  inhibit secretion of only the 
immunoglobulin  (Ig)  bearing  the  relevant  idiotype.  In  contrast,  syngeneic TNP- 
reactive cytolytic T  lymphocytes (CTL) inhibit antibody secretion by TNP-binding 
MOPC  315  cells but not by MPC  11  cells in the presence of soluble TNP-keyhole 
limpet hemocyanin (KLH), and this inhibition probably represents a  prelytic effect 
of the CTL. Such TNP-reactive CTL, in the presence of TNP-KLH, inhibit both IgA 
and  IgG secretion by the  MOPC  315-MPC  11  hybrid, which is consistent with a 
prelytic effect. Thus, myeloma hybrids are a  useful tool for investigating the effector 
function  of regulatory  T  cells.  These  results  are  discussed  with  reference  to  the 
mechanisms  of action  of regulatory T  cells  and  their  relevance  to  modulation of ABBAS, BURAKOFF,  GEFTER,  AND GREENE  977 
physiologic humoral immune responses. 
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